– Last subject completed study in late 2021 with topline results expected in early 2022 – – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal – NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies…


Previous articlePsychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top
Next articlePT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom